Objectives/Hypothesis: To determine if the spontaneous reinnervation that characteristically ensues after recurrent laryngeal nerve (RLN) injury could be selectively promoted and directed to certain laryngeal muscles with the use of neurotrophic factor (NF)-secreting muscle stem cell (MSC) vectors while antagonistic reinnervation is inhibited with vincristine (VNC).
INTRODUCTION
Loss of vocal fold function due to neurological injury with incomplete recovery can result in dysphonia and dysphagia. If there is bilateral loss of function then airway compromise can result as well. 1, 2 Current therapies for vocal fold paralysis (VFP) fail to reliably restore functional motion, and therefore are suboptimal. Thus, the search for a new treatment for VFP is warranted. The goal of this thesis is to investigate muscle stem cell (MSC)-based therapy for the treatment of VFP. These studies are preliminary in nature, to determine if neural regeneration can be influenced with such an approach. Although an MSC-based model is unlikely to restore full vocal fold motion as a primary therapy for recurrent laryngeal nerve (RLN) injury, such an approach may serve as a minimally invasive adjuvant therapy for directing reinnervation after VFP reinnervation procedures, or for promoting reinnervation of laryngeal replacement models such as laryngeal transplantation or the conceptual stem cell-based tissue engineered larynx.
Recent studies suggest that persistent vocal fold immobility after RLN injury is not due to lack of reinnervation, but due to the aberrant, spontaneous reinnervation that ensues after nearly all RLN injuries. 3, 4 Despite spontaneous reinnervation after RLN injury being widely recognized, the source of reinnervation is debatable. Sources such as the ipsilateral RLN, 4, 5 autonomic nerves (adrenergic and nonadrenergic), 6, 7 and the superior laryngeal nerve (SLN) 8 have independently been implicated as primary sources of laryngeal reinnervation after RLN injury. Certainly, the functional outcome attained with spontaneous reinnervation after RLN injury depends not only on the on the primary source of reinnervation, but also on the relative degree of reinnervation to the denervated adductor and abductor muscles. The importance of this relationship is probably best exemplified in studies attempting to reanimate the larynx via surgical reinnervation after RLN injury. For example, proximal RLN transection followed by primary neurorrhaphy consistently fails to result in normal vocal fold motion (abduction and adduction) due to misdirected axonal regeneration of the adductor and abductor fibers resulting in synkinesis. 9 In contrast, surgically guiding phrenic to posterior cricoarytenoid (PCA) muscle reinnervation with simultaneous nonphrenic laryngeal adductor muscle reinnervation is an approach that has been investigated for years, 10, 11 and recently shown to lead to restoration of abductor motion in select cases. 11 Thus, based on the conceptual need to promote differential reinnervation to the adductor and abductor muscles after RLN injury, the goal of this study was to use minimally invasive techniques to enhance physiologic pathways involved in neural regeneration to selected laryngeal muscles, while preventing functional antagonistic reinnervation.
The development of this minimally invasive model was based on previous work by Flint and colleagues demonstrating that spontaneous reinnervation can be enhanced with delivery of a neurotrophic factor (NF) at the denervated laryngeal muscle studies, [12] [13] [14] and the work by Paydarfar and Paniello that showed vincristine (VNC) can inhibit reinnervation to selected muscles. 15 Although the studies by Flint and colleagues directly injected NF-expressing plasmid vector into the denervated hemilarynx and demonstrated successful enhancement of reinnervation when the plasmid was expressed, we chose not to use plasmid alone because of its innate limitations of unreliable and inefficient sustained gene expression. Based on our laboratory's previous investigations demonstrating that autologous MSCs will survive in a denervated hemilarynx in an animal model for at least a 2-month period, 16, 17 we anticipated that using MSC vectors for NF delivery would lead to selectively increased spontaneous reinnervation if a stable gene transfer vector were identified for the MSCs. Furthermore, based on prior work by Paydarfar and Paniello, 15 our laboratory had studied VNC as a neurotoxin to prevent antagonistic reinnervation, and an optimal dose and concentration of VNC was identified that could be injected to the rat laryngeal muscles without histologically affecting reinnervation of adjacent muscles. 18 Thus, we anticipated being able to use these minimally invasive approaches to selectively enhance reinnervation to certain muscles after RLN injury, while chemically inhibiting functional reinnervation to antagonistic abductor muscles. In the proposed model, it was anticipated that application of VNC to inhibit spontaneous antagonistic PCA reinnervation would thereby unmask the innate spontaneous reinnervation to the adductor complex; furthermore, NF-secreting MSCs in the adductor complex may selectively augment innate adductor reinnervation. Of course, outcomes would be expected to be directly related to the source of adductor spontaneous reinnervation. For example, tone and midline migration alone would be anticipated with predominantly autonomic reinnervation, adduction during phonation/ deglutition with adductor RLN fiber reinnervation, inspir-atory adduction with abductor RLN fiber reinnervation, and some combination of functions may result if a variety of reinnervation source(s) were involved. Thus, the overall goal of the study was not to restore normal vocal fold motion, but rather to determine if neural regeneration after RLN injury can be selectively guided with a minimally invasive MSC-based approach and to determine outcomes in an animal model.
Hypothesis
It was hypothesized that an NF with the potential to enhance RLN recovery could be identified using MSC survival assays and vagus motoneuron outgrowth testing; furthermore, it was hypothesized that therapeutic delivery of identified NF via autologous MSC vectors could be used to selectively enhance reinnervation after RLN injury, and when antagonistic reinnervation (synkinesis) is simultaneously inhibited, vocal fold adductor activity may be detectable.
Thus, this thesis involved three specific aims (please see Fig. 1 
for overview):
Aim 1: To use an MSC survival assay followed by vagus motoneuron outgrowth testing to identify an individual NF that promotes muscle stem cell survival and enhances vagus motoneuron regeneration.
Aim 2: To construct a gene transfer vector encoding therapeutic NF, with resultant NF secretion from transduced primary MSCs in vitro.
Aim3. To determine post-RLN injury therapeutic outcomes in a time-dependent fashion after NF-secreting autologous MSCs are injected into acutely denervated laryngeal adductor muscles to promote reinnervation, and localized neurotoxin is injected into the PCA to inhibit antagonistic reinnervation.
MATERIALS AND METHODS

Experiments to Address Aim 1
MSC culture technique. MSC survival assays were developed to test the impact that the NFs of interest have on MSC survival. First, MSC cultures were established as previously described. 16, 17 In brief, starting with 1 gram of rat skeletal muscle, connective tissue was trimmed and muscle dissected into 1 mm pieces or smaller. Excess Dulbecco's phosphate-buffered saline (D-PBS) was aspirated, and 4 mL of 0.2% collagenase type I (Worthington Biochemical, Lakewood, NJ) was added, incubating it at 37 C for 2 hours. The cells were then titurated, rinsed in D-PBS, and distributed among the wells of a 6-well 0.2% Matrigel-coated plate (Fisher Scientific, Chicago, IL) containing myogenic medium consisting of Dulbeco's Modified Eagle Medium (Fisher-Scientific), 1% penicillin and streptomycin (Gibco Invitrogen, Carlsbad, CA), 10 ng/mL insulin-like growth factor 1 (IGF-1) (Gibco Invitrogen), 2.5 lg/mL amphotericin B (Sigma-Aldrich, St Louis, MO), 20% heat-inactivated fetal bovine serum (Valley Biomedical, Winchester, VA), 10% heat-inactivated horse serum (Gibco Invitrogen), 0.1% chick embryo extract (Accurate Chemical and Scientific Corp. Westbury, NY). Cells were grown at 37 C and 5% CO 2. Preplating steps were done as each passage to maintain a balanced population of muscle progenitor cells. Passaging of the cultures (1:3 split) was carried out at subconfluency (70% confluency) to avoid maturation of the cells and myotube formation.
Homogeneity of MSC cultures was characterized by examining CD56 cell surface expression employing fluorescence activated cytometric analysis (FACS) (Becton Dickinson, San Jose, CA).
MSC Survival Assays
Although NFs are defined as secreted proteins that promote the survival, growth, and/or differentiation of neurons, the NFs selected for these studies were selected based on their known potential for dual myotrophic and neurotrophic effects. Based on these criteria and a previous investigation on adjuvant therapies for optimizing MSC survival in the denervated larynx, 17 vascular endothelial growth factor (VEGF), IGF-1, ciliary neurotrophic factor (CNTF), and neurturin (NTN) were selected for the MSC survival investigations.
After primary MSC cultures had been established as described above, MSCs were cultured in serum-free medium for 24 hours, after which 5 Â 10 5 cells were plated in 6-well culture plates. Serum-free medium was then supplemented with individual growth factors including recombinant human IGF-1 (100 ng/ mL) (Gibco Invitrogen), recombinant rat VEGF (100 ng/mL) (Biosource International, Inc., Camarillo, CA), recombinant CNTF (100 ng/mL) (Biosource International, Inc.), recombinant human NTN (100 ng/mL) (Biosource International, Inc.), or saline. Cell cultures were maintained in a 37 C, 5% CO 2 , humidified incubator. Cells were harvested 48 hours later and cell survival assessed by trypan blue exclusion. All experiments were conducted in triplicate, using three different primary cell lines. Student t test was used to compare NF-mediated MSC survival to that of controls.
Motoneuron culture technique. Six-well plates of rat motoneuron cultures derived from tenth cranial motor nuclei were created by incorporating methodology of Kivell and colleagues 19 with significant modifications. 20 In brief, rat motoneurons were purified from the ventral brainstem of rats on postnatal day 1, with dissection including motoneurons from the nuclei of cranial nerve X (CNX), with minimal extension into IX and XII to ensure that all CNX motoneurons were encompassed in the dissection. The specimen was immediately incubated in hibernate-A (Hib-A) (Brainbits, Springfield, IL) with 1X B27 (2% v/v; Gibco Invitrogen) on ice. Brainstem tissue was dissociated after trypsinization (0.05%) (Sigma-Aldrich) with 0.1 mg/mL DNAse I (Roche, Indianapolis, IN) added, repetitive centrifuging in Hib-A, and trituration with fire-polished Pasteur-pipets until a single cell suspension was obtained. Motoneuron enrichment over a 10% OptiPrep (Accurate Chemical and Scientific Corp.) density gradient in Hib-A was then performed, centrifuging at 400g for 25 minutes, removing the upper fraction, and then centrifuging at 700g for 10 minutes to pellet. Cells were resuspended in Hib-A, centrifuged, and then resuspended in 1.5 mL growth media (neurobasal-A with 1X glutamine [Gibco Invitrogen], 1X B27 supplement, 0.45X 2-mercaptoethanol [Gibco Invitrogen], 50 U/mL penicillin/streptomycin [Gibco Invitrogen]) and plated on 22-mm polyornithine (Sigma-Aldrich) and laminin (Gibco Invitrogen)-coated tissue 5-mm culture-treated coverslips. For additional purification, the cells were allowed to adhere while incubating at 37 C for 30 minutes. The coverslips were then removed and washed in prewarmed 37 C plain neurobasal-A (Gibco Invitrogen), placed into a 96-well dish prefilled with 3-mL growth media and incubated at 37 C. to identify an NF that promotes MSC survival and enhances vagus motoneuron outgrowth. The identified NF is encoded into a lentiviral vector (2A). MSCs are then transduced with the lentiviral vector encoding the NF, and NF secretion from primary MSCs is optimized (2B). Finally, recurrent laryngeal nerve (RLN) transection injury is treated by introduction of the NF-secreting MSCs into the denervated adductor complex, while the posterior cricoarytenoid (PCA) muscle is injected with a neurotoxin (vincristine) to prevent antagonistic reinnervation (3). NTN ¼ neurturin; CNTF ¼ ciliary neurotrophic factor; IGF-1¼ insulin-like growth factor 1; VEGF ¼ vascular endothelial growth factor; EGFP ¼ enhanced green fluorescent protein.
Motoneuron outgrowth assessment. Because CNTF demonstrated the greatest impact on MSC survival, this series of experiments focused on CNTF at differing concentrations to determine if there was an optimal concentration of CNTF that would induce CNX outgrowth effects in vitro. Recombinant rat CNTF was added at physiologic concentrations (0.5, 5, 50, or 500 ng/mL) every 24 hours for 3 days. The negative control group had saline alone added every 24 hours. Phase-contrast images were captured using the Nikon Upright Spotcam (Nikon, Tokyo, Japan), with ImageJ software (http://rsbweb. nih.gov/ij/) used for analysis. Neurite length (summation of the lengths of all neurites per neuron) was measured at 3 days. Only those neurons with a neurite length at least twice the diameter of the soma were included in this analysis, involving six motoneurons per treatment group. In addition to analyzing neurite length, the number of side branches (primary branches) and the longest neurite per motoneuron was determined ( Fig. 2 ). Experiments were performed in triplicate.
Experiments to Address Specific Aim 2
Construction of lentiviral vector encoding NF. NFencoding constructs were based on the self-inactivating cytomegalovirus (CMV)-driven CNTF lentiviral vector kindly provided to our laboratory by Dr. Bas Blits. 21 Dr. Kenneth Cornetta, the director of the Indiana University Vector Production Facility, kindly provided our laboratory with lentivirus of differing pseudotypes, with the lenti-adapted envelopes 4070A and RD114 generated by Dr. Cornetta using plasmids kindly provided by Derek Person and Arthur Nienhuis of Memphis, TN. 22 Transduction efficiencies with primary MSCs were then established with recombinant lentiviral vector pseudotyped with VSVG, pCAG-LPPP2, RD114, or amphotropic (pCAG 4 AMP) envelopes. The CNTF sequence of interest was cloned into the Bam HI site, just upstream from the enhanced green fluorescent protein (EGFP) reporter gene, such that EGFP expression would function as a marker of transduction. As previously described, 23 recombinant lentivirus was produced by transient triple transfection of 293T cells. After seeding cells in 75-cm 2 tissue culture flasks 24 hours before transfection in D-10 zmedium, and refeeding with D-10 medium 2 hours before transfection, 293T cells were transfected with the NF-encoding transfer plasmid, packaging plasmid, and amphotropic envelope plasmid at a ratio of 1:1:0.2 using calcium phosphate method (Profection kit; Promega, Madison, WI). Approximately 16 hours after transfection, cells were refed with fresh medium, and 48 hours after transfection vector supernatants were collected, centrifuged, and pellets resuspended in phosphate-buffered saline (PBS). The vector was filtered, suspended in 1 mL of D-10 and stored at À80 C. Viral titers were determined as previously described. 20 In brief, 24 hours after 1 Â 10 5 D17 cells were grown in a 6-well plate, and serial dilutions of concentrated viral stock were placed on cells and centrifuged at 2600 rpm for 1 hour at 32 C. The percentage of EGFP positive cells was determined with FACS (Becton Dickinson), and based on the percentage of positive cells and viral dilutions, viral titers were determined.
Optimize NF secretion from transduced primary MSCs in vitro. To attain this goal, MSC cultures were established as described in Experiments to Address Specific Aim 1 above and previously. 16, 17 Transduction was performed with MSCs at 50% confluency in 100-mm plates. MSCs were incubated in lentiviral supernatant containing polybrene (8 lg/mL) (Sigma-Aldrich) for 4 hours at 37 C. All infections were done in triplicate. When the cells demonstrate EGFP expression by fluorescent microscopy (approximately 72 hours post-transduction), cells were sorted by FACS for MSC-specific marker CD56, and transduction marker EGFP. Sorted cells were plated on 100-mm plates, and expression of CNTF was determined with quantitative enzyme-linked immunosorbent assay (ELISA) when cells reached 70% confluency, as previously described by Hu et al. 24 In brief, approximately 10 6 transduced MSCs were treated with protease inhibitor (Sigma-Aldrich), centrifuged, and the supernatant collected. After reaction with protein assay agent (Bio-Rad, Richmond, CA), protein concentration of each sample was measured by spectrophotometer. Ninety-six-well miniplates were coated with monoclonal mouse CNTF-antibody diluted in PBS buffer overnight at 4 C. The plates were incubated overnight at room temperature with blocking solution (1% bovine serum albumin, 5% sucrose, and 0.05% NaN 3 in PBS). With interceding washes (0.05% Tween 20 in PBS, pH 7.4), the plates underwent 2-hour incubations with double aliquots of conditioned medium, protein extract, biotinylated polyclonal goat anti-CNTF factor antibody, and avidin-biotin complex (ABC) reagent (Vectastain; Vector Laboratories, Burlingame, CA). Horseradish peroxidase activity was detected using 3,3 0 ,5,5 0 -tetramethylbenzidine (MP Biomedicals, Irvine, CA). After 30 minutes incubation, color reaction was stopped by adding H 2 SO 4 . Absorbance at 450 nm was measured using an ELISA reader (Bio-Rad). Using serial dilutions of known amounts of CNTF, the color reaction was used to construct a standard curve, and CNTF levels in the samples were determined. All experiments were repeated in triplicate.
Experiments to Address Specific Aim 3
Animal model of RLN injury. To address specific aim 3, 60 Fischer 344 rats were anesthetized with intraperitoneal ketamine (75 mg/kg) and xylazine (10 mg/kg). The left RLN was identified and transected, with a 1-cm nerve segment removed. A total of 1 g of sternocleidomastoid muscle was harvested at the time of denervation and placed immediately in myogenic medium. Before the animals awoke from anesthesia, unilateral vocal fold immobility was confirmed. The muscle biopsy was then used to culture autologous MSCs, which were tranduced with lentiviral vector (see Experiments to Address Specific Aim 1 and 2 for MSC culture technique and lentiviral transduction For the experiments, the longest neurite (bracket) was measured as well as the number of primary and secondary branches. In addition, the sum of the total length of all neurites (arrowheads and bracket) was determined from the periphery of the soma (*). methods, respectively). At approximately 3 weeks after the denervation procedure, lentiviral-transduced MSCs were sorted with FACS (Becton Dickinson) for expression of EGFP (a marker of transduction) and CD56 (a marker of myogenic lineage-committed myoblasts), with sorted MSCs used for injection. This time period was selected because it was ample time for therapeutic levels of transduced MSCs to be developed, and it is an ideal time to administer a neurotoxin to inhibit ongoing reinnervation as demonstrated by our previous studies. 18 For the injection procedure, animals were again anesthetized, and approximately 10 6 NF-expressing MSCs, or 10 6 control MSCs (expressing EGFP for cell tracking) suspended in saline were injected into the midbody of the denervated thyroarytenoid (TA) muscle of each animal via midline thyrotomy, while saline controls received saline alone. Half of the animals from each group received injections into the denervated PCA muscle with 4 ll of VNC (0.5 lg/lL) aqueous solution to inhibit spontaneous reinnervation of that muscle, whereas the other animals received saline alone (Table I) . At 2 months or 4 months after the RLN transection procedure, six animals from each group were randomly selected to undergo anesthesia with videorecording of vocal fold motion and rating of motion in a blinded fashion. The vocal fold abduction was assessed during quiet respiration, and laryngeal adduction was assessed after inducing laryngospasm with a 20gauge angiocatheter and during spontaneous glottic closure (e.g., with swallowing or coughing,). Laryngeal electromyography (LEMG) was performed on both the TA complex and PCA muscles to assess for the presence and pattern of reinnervation. For LEMG testing, a Nicolet Viking Quest electromyography machine was used with the amplitude set to 50 lV, with 10 ms sweep speeds. A 25-gauge bipolar concentric needle electrode was used for intramuscular testing, with a clamp placed on the exposed lateral neck muscle for grounding. To ensure optimal needle insertion, the skin was incised and strap muscles were retracted to allow direct visualization of the larynx during the study. Each PCA was identified directly via a posterior approach while gently retracting the larynx contralaterally, and each TA was first identified and tested by insertion of the needle via the cricothyroid membrane, and then additional confirmation of correct needle placement (to ensure optimal signaling) was done by direct visualization through a midline laryngofissure. Recruitment of the TA was rated during laryngospasm, and recruitment for the PCA was rated during inspiration, with rating scales from 0 to 4 as previously described by Koufman and Walker. 25 After individual muscle testing was done, the LEMG needle was placed in the left TA muscle while a scalpel was used to transect the incoming neural supply to the larynx by sequentially transecting the left RLN, the left SLN, the right RLN, and the right SLN sources until the left TA LEMG activity was silenced. Animals were then euthanized, larynges harvested, and frozen on liquid nitrogen. The tissue was sectioned as described by Nakagawa et al. 14 Sections were analyzed under fluorescent microscopy to confirm EGFP expression from the TA in the MSC-and NF-MSC-treated groups. In addition, immunohistochemistry assessment of motor endplate to nerve contact was done using primary conjugated bungarotoxin antibody (Gibco Invitrogen) and beta-III tubulin antibody (Covance, Princeton, NJ) to demarcate the motor endplates and neurons, respectively. At 4 months, muscle samples were taken bilaterally from the TA complex and PCA for CNTF and other NF detection via reverse transcriptase-polymerase chain reaction (RT-PCR). Student t test and Fisher exact test were used for statistical analysis of outcomes, with significance set at P < .05. 
RESULTS
Results
All animals underwent left RLN transection injury 3 weeks prior to the therapeutic injections. Follow-up time periods (right) are relative to the time of RLN Injury.
TA ¼ thyroarytenoid muscle complex; PCA ¼ posterior cricoarytenoid muscle; Ctl ¼ control; MSC ¼ control muscle stem cells with tracking marker EGFP; EGFP ¼ enhanced green fluorescent protein; NF-MSC ¼ neurotrophic factor-secreting muscle stem cells; CNTF ¼ ciliary neurotrophic factor; VNC ¼ vincristine; RLN ¼ recurrent laryngeal nerve. Fig. 3 . Muscle stem cell (MSC) survival based on the neurotrophic factor additive. The average of three survival assay experiments demonstrates a mean myoblast survival of 93% when MSCs were incubated with ciliary neurotrophic factor (CNTF) versus 45% in the controls (P ¼ .02). Although the other factors also appeared to enhance survival, the difference was not significant (P > .05). IGF-1 ¼ insulin-like growth factor 1; VEGF ¼ vascular endothelial growth factor; NTN ¼ neurturin. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Results for Specific Aim 1B: Determine the Effect of CNTF on Motoneuron Outgrowth
Motoneuron outgrowth testing. Because CNTF demonstrated the greatest impact on MSC survival, this series of experiments focused on CNTF at differing concentrations to determine the effect of CNTF on CNX outgrowth in vitro. Recombinant rat CNTF was added at physiologic concentrations (0.5, 5, 50, or 500 ng/mL) every 24 hours for 3 days to the vagus motoneuron cultures, as described in the Materials and Methods section. Results demonstrated that although CNTF at a concentration of 50 ng/mL resulted in the greatest mean motoneuron neurite length (Fig. 4A) , the difference did not reach significance. However, addition of CNTF at the same concentration (50 ng/mL) resulted in longer maximal neurite length than that of the other CNTF groups and the controls (P ¼ .001) ( Fig. 4B ). In addition, a CNTF concentration of 50 ng/mL resulted in significantly more neurite branching with a mean of 6.6 branches per neurite compared to 5.7 branches in the controls (P ¼ .012) ( Fig. 4C ). In addition to these CNTF investigations, our laboratory has also previously studied and reported the effects of other neurotrophic factors on CNX motoneuron outgrowth, with no factor identified that has greater outgrowth effect than that of CNTF. 20 Plasmid vector. These investigations aimed to determine the optimal vector for introducing CNTF-encoding genome into MSCs. Although plasmid vectors lack immunogenicity, they are plagued by inefficient gene transfer. We hypothesized that an ex vivo gene delivery may circumvent the issue of low transduction rates, as primary MSCs proliferate rapidly in culture, allowing a therapeutic number of MSCs to be attained despite low gene transfer efficiency. To test this hypothesis, primary MSCs derived from 250-g male Fischer 344 rats were grown in culture to a cell count of 10 5 . Cells were then transfected with EGFP-expressing plasmid, and after 48 hours FACS (Becton Dickinson) was used to determine the percentage of cells with EGFP expression. This demonstrated tranfection efficiency with the plasmid to be 8%. After sorting the EGFP-expressing MSCs, they were main-tained in culture for 3 weeks. MSC fluorescence rapidly decreased over that time period, with no EGFP detectable at 3 weeks, suggesting plasmid extrusion. Thus, based on this rapid rate of plasmid extrusion, it was concluded that plasmid vector is suboptimal for these investigations.
Viral vector. In previous in vivo MSC survival optimization studies, we demonstrated MSCs can be transduced with an EGFP-expressing retroviral vector. 17 Although the retroviral vector could be used for the experiments in this protocol, lentiviral vector is generally preferable for its high transduction efficiency and low risk of mutagenesis. Dr. Bas Blits generously donated a selfinactivating CMV-promoted CNTF-EGFP construct to our laboratory (Fig. 5A ). 21 Dr. Kenneth Cornetta, the director of the Indiana University Vector Production Facility, kindly provided our laboratory with lentivirus of differing pseudotypes, with the lenti-adapted envelopes 4070A and RD114 generated by Dr. Cornetta using plasmids kindly provided by Derek Person and Arthur Nienhuis of Memphis, TN. 22 Transduction efficiencies with primary MSCs were then established with recombinant lentiviral vector pseudotyped with VSVG, pCAG-LPPP2, RD114, or amphotropic (pCAG 4 AMP) envelopes. The first three pseudotypes (VSVG, pCAG-LPPP2, and RD114) each demonstrated individual trial transduction efficiencies of <75%, whereas the lentiviral vector pseudotyped with amphotropic envelope transduced primary MSCs with over 90% efficiency in three consecutive trials (Fig. 5B ). ELISA confirmed that the MSCs transduced with CNTF-expressing amphotropic lentiviral vector reliably secreted CNTF in culture when compared to control MSCs. These findings supported the selection of the amphotropic pseudotyped recombinant lentiviral vector as a CNTF gene delivery vector for the experiments to address specific aim 3.
Preliminary Studies for Experiments to Address
Specific Aim 3 VNC effects in vivo. Before initiating the proposed experiments to address specific aim 3, an optimal concen-tration of VNC was identified that would not negatively affect the spontaneous reinnervation and MSC survival in adjacent laryngeal muscles. In preliminary studies on RLN injury, it was noted that RLN reinnervation to the TA typically preceded PCA reinnervation, and waveforms demonstrated larger amplitude and intensity at various time points. Thus, we first investigated VNC for the inhibition of TA reinnervation; the results of this investigation have recently been published. 18 Directly pertinent to the experiments to address specific aim 3, the first goal of the investigation was to determine if low-dose (0.5 lg/ lL) VNC could selectively inhibit spontaneous PCA reinnervation without impairing reinnervation to the ipsilateral TA muscle complex. In addition, a second goal of the experiments was to determine if VNC injections into the PCA would adversely affect MSC survival when MSCs were injected into the ipsilateral TA. Thus, these preliminary studies were done to ensure that VNC effects on the ipsilateral TA muscle complex would not pose an obstacle to proceeding with the experiments to address specific aim 3. This investigation involved 20 male Fischer 344 rats. For this pilot investigation, all animals underwent left RLN transection and sternocleidomastoid (SCM) muscle biopsies under anesthesia with ketamine/xylazine. From the SCM biopsies, MSC cultures were derived and MSCs were transduced with EGFP lentiviral vectors. Three weeks after RLN injury, the denervated TA of each animal was injected with MSCs (n ¼ 10) for the study group or saline (n ¼ 10) for the controls; for each group, with spontaneous reinnervation after the ipsilateral PCA had been treated with VNC. Note the reinnervation of (C) is similar to the TA reinnervation of (D) (control), suggesting that the VNC treatment did not affect TA reinnervation. (D) Control denervated TA with spontaneous reinnervation after ipsilateral PCA received saline alone. half the animals (n ¼ 5) simultaneous received injections into the ipsilateral PCA with 4 lL of VNC (0.5 lg/lL), whereas saline was injected into the PCA in the remaining animals (n ¼ 5) in each group. One month later, animals were evaluated in a blinded manner with direct laryngoscopy and LEMG under general anesthesia, followed by euthanasia. Laryngeal specimens were harvested, fixed, and sectioned. Results demonstrated that VNC was effective in preventing reinnervation to the PCA, with three animals having fibrillations/fasciculations only (no recruitment) ( Fig. 6A ) and one animal with 1þ recruitment. The saline-treated animals had PCA motor units that were smaller in amplitude than the TA motor units, but all had evidence of reinnervation (Fig.  6B) . Reinnervation of the TA was similar among all animals, regardless of whether VNC or saline was injected into the ipsilateral PCA (Fig. 6C,D) , suggesting VNC had not influenced reinnervation of the ipsilateral TA. Regarding MSC survival, viable MSCs were detected throughout all of the MSC-injected TA muscles. The TA complexes demonstrated no difference in fluorescent intensity (EGFP expression) under fluorescent microscopy indicating that ipsilateral VNC PCA injection did not adversely impact MSC viability.
Results for Specific Aim 3: Investigating CNTF-Expressing MSCs With VNC in an Animal Model of RLN Injury
Due to a standard attrition rate (5%-10%) associated with multiple survival surgeries in the rat model, the final number of animals in each group varied slightly, with groups at the time of final assessment ranging from four to six animals per treatment condition. Vocal fold motion evaluation, LEMG testing, and immunohistochemistry analysis were completed with the principal investigator blinded to each animal's treatment group. As anticipated, the TA demonstrated strong fluorescent intensity at both time points, with minimal change in intensity demonstrated over time ( Fig. 7) , suggesting excellent MSC postinjection survival.
2-Month Outcomes
Videolaryngoscopy findings. On videolaryngoscopy assessment, none of the animals had vocal fold abduction during respiration. Of the saline controls, none had detectable vocal fold adduction. One animal in the CNTF group had weak adduction during laryngospasm, with complete glottic closure but no motion during quiet respiration. None of the remaining animals in the CNTF group or other groups (EGFP, EGFP-VNC, CNTF-VNC) had detectable motion.
LEMG results. LEMG assessment of recruitment and waveform morphology of the TA was graded based on active firing during laryngospasm, whereas the PCA activity was tested during quiet respiration. The TA and PCA muscle LEMG recruitment ratings for each group are summarized in Figure 8 . In brief, the CNTF group had greater recruitment in the TA muscle complex and the PCA muscle than the saline controls (P ¼ .02 and .04, respectively). The CNTF-VNC group also had greater recruitment in the TA muscle complex than the saline controls (P ¼ .04). As was anticipated, there was minimal recruitment (0-1þ) in the PCA muscles of the animals that had received VNC injections into the PCA, but when compared to the saline controls the difference did not reach significance (P ¼ .05 and .07, respectively). When looking at waveform size based on treatment groups, 40% . Upon intraoperative evaluation of the laryngeal anatomy prior to euthanasia, all animals were noted to have a tract of regenerated tissue extending from the transected RLN stump to the larynx, suggestive of a regenerated RLN segment. Immediately prior to euthanasia, while monitoring the left TA with continuous LEMG, transecting this regenerated ipsilateral RLN silenced the TA in 15 animals, whereas seven animals required transection of the ipsilateral SLN before the left TA activity silenced. One animal died prior to obtaining useful data on the innervating source.
Motor endplate to nerve contact. Motor endplate to nerve contact was assessed with immunohistochemistry using bungarotoxin for motor endplate identification and beta III tubulin for nerve staining. Six mid-TA axial sections were reviewed for each treatment group, and maximum motor endplate to nerve contact noted within those sections was classified as denervated (<33% of motor endplates with nerve contact), partially reinnervated (approximately 33%-4-66% of motor endplates with nerve contact), or strongly reinnervated (>66% of motor endplates with nerve contact) ( Fig. 9 ). At 2 months, all of the stem cell-treated groups (EGFP, EGFP-VNC, CNTF, CNTF-VNC) demonstrated partial reinnervation. Four out of five of the control left TA specimens demonstrated partial reinnervation, whereas one was classified as denervated. Fig. 8 . Laryngeal electromyography (LEMG) results at 2 months. LEMG recruitment ratings were on a scale from 0 to 4þ, with all ratings performed with the investigator blinded to the treatment that the animal had received (see Materials and Methods for further details). Average recruitment scores are demonstrated for the thyroarytenoid (TA) muscles bilaterally (above) and the posterior cricoarytenoid (PCA) muscles bilaterally (below). There was no significant difference in recruitment on the right (normally innervated) side represented on the right side of the bar graphs; however, the left TA and PCA groups showed recruitment patterns that varied in relation to the type of injection given to the muscle (*P < .05). EGFP ¼ enhanced green fluorescent protein; CNTF ¼ ciliary neurotrophic factor; VNC ¼ vincristine.
4-Month Outcomes
Videolaryngoscopy findings. On videolaryngoscopy assessment, none of the animals had vocal fold abduction on the paralyzed side. Six of the 20 animals in stem cell-treated groups (1/4 in the EGFP group, 1/5 in the CNTF group, 2/6 in the EGFP-VNC group, and 2/5 in the CNTF-VNC group), and one animal (1/5) in the saline control group appeared to have weak adductor activity during laryngospasm. In seven stem cell-treated animals (1/4 EGFP, 2/5 CNTF, 2/6 EGFP-VNC, and 2/5 CNTF-VNC), there was a brief adductor twitch during respiration, which was not present in the control animals (P < .01). In all of these animals, LEMG findings demonstrated firing in the TA complex that corresponded with the adduction. Although the adductor firing varied in timing, there was minimal ipsilateral oppositional PCA firing simultaneously in the animals with adductor motion, suggesting unopposed TA firing was responsible for the motion in these animals. Figure 10 is a representative figure demonstrating the timing of the adductor motion relative to the firing of the denervated TA and PCA muscles on LEMG.
LEMG results. As with the 2-month assessments, LEMG rating of recruitment and waveform morphology of the TA was done during active firing on laryngospasm, whereas the PCA activity was tested during quiet respiration, and the investigator was blinded to the treatment group of the animal being tested. Bilateral TA and PCA muscle LEMG recruitment ratings for each group are summarized in Figure 11 . In brief, all the left TA and PCA muscles demonstrated greater recruitment than that at 2 months (Fig. 8 ). However, there was no significant difference between the recruitment in the saline groups and the stem cell-treated groups for either the TA (Fig. 11 , above) or the PCA (Fig. 11, below) . The morphology of the waveforms also varied between the 2month and 4-month animals, with more of the 4-month TA and PCA muscles demonstrating giant units, often with polyphasic potentials. When looking specifically at treatment groups, 60% (3/5) of the saline controls demonstrated giant motor units in the TA, whereas 80% Fig. 9 . Motor endplate to nerve contact. Representative high power (60Â) confocal microphotographs of immunohistochemistry slides with bungarotoxin (blue) demarcating the motor endplates along the myofibers (left), and the middle figures demonstrating staining with the neuronal specific marker, beta III tubulin (red). On the right, the two images are merged; those sites with colocalization of the bungarotoxin (blue) and beta III tubulin (red) represent motor endplates with nerve contact (reinnervation), with the areas of bungarotoxin alone (blue) representing denervated motor endplates. (A1-A3) Section series classified as denervated (<33% of motor endplates with nerve contact). (B1-B3) Partially reinnervated section (33%-66% of motor endplates with nerve contact). (C1-C3) Strongly reinnervated section (>66% of motor endplates with nerve contact). Note the high variability in the number of motor endplates between sections, with the middle series (B1-B3) having the greatest number of motor endplates within the section. before the left TA activity silenced. Two animals died intraoperatively before the innervation source could be determined. Two of the animals with SLN reinnervation sources were saline controls, whereas seven were stem cell treated. No relationship was found between the SLN reinnervation and treatment with the CNTF-MSCs.
Motor endplate to nerve contact. As with the 2-month TA specimens, motor endplate to nerve contact was assessed with immunohistochemistry using bungarotoxin for motor endplate identification and beta III tubulin for nerve staining, with sections classified as denervated (<33% of motor endplates with nerve contact), partially reinnervated (approximately 33%-66% of motor endplates with nerve contact), or strongly reinnervated (>66% of motor endplates with nerve contact) ( Fig. 9 ). At 4 months, eight of the stem cell-treated animals were classified as strongly reinnervated (3/5 CNTF, 2/4 EGFP, 3/5 CNTF-VNC), with the remaining specimens and all of the saline controls (5/5) partially reinnervated. Thus, 6/10 of the CNTF-MSC-injected TAs demonstrated strong reinnervation based on immunohistochemistry (P ¼ .02). Within the CNTF-treated animals, high variability was noted in the percentage of motor endplates with nerve contact within individual TA specimens.
RT-PCR
At 4 months, to determine if CNTF expression from the muscle was still enhanced in the CNTF-MSCinjected TAs, a small sample of denervated (left) TA muscle from each TA treatment group (saline, EGFP, CNTF) was attained. Two samples were pooled from each treatment group. The RT-PCR trials were run in triplicate, with glyceraldehyde-3-phosphate dehydrogenase as a standard internal control. Results confirmed highly upregulated CNTF expression from the CNTF-MSC-injected denervated TA at 4 months after RLN injury (Fig. 12 ). There was no significant difference in CNTF expression between the control MSC (EGFP)injected group and the saline control. Because brief adductor motion was detected in seven of the stem celltreated animals, including both the EGFP-and CNTF-MSC-injected groups, additional RT-PCR testing was completed to determine if NF expression was altered in the EGFP-MSC-injected TA muscles. No difference was detected in IGF-1, brain-derived neurotrophic factor (BDNF), or glial cell-derived neurotrophic factor (GDNF)) expression between the EGFP-MSC and saline control groups. However, the CNTF-MSC-injected TA Fig. 10 . Laryngeal electromyography (LEMG) patterns associated with brief adduction during respiration. Characteristic LEMG firing patterns at 4 months that correlated with videolaryngoscopy findings of an adductor twitch during respiration. Gray shaded area demarcates the inspiratory posterior cricoarytenoid (PCA) muscle recruitment with giant motor units (3þ), whereas the solid arrow denotes a burst of increased firing activity in the thyroarytenoid (TA) muscle with relatively little antagonistic firing from the PCA, leading to brief adduction during inspiration. The PCA was characteristically silent between inspiratory firing, whereas the TA demonstrated continuous firing at baseline. specimens demonstrated increased expression of IGF-1 and BDNF ( Figure 13A,B , respectively) when compared to the saline controls and EGFP-MSC groups.
DISCUSSION
The current investigations started with using in vitro assays for screening NFs that may have therapeutic applications for management of RLN injury. The MSC survival assay is a model in which MSCs are placed in culture in a state of serum deprivation (which slowly induces cell death) to determine which additive factors have the greatest positive effect on survival. These in vitro investigations demonstrated CNTF to have greater survival-promoting effects on the MSCs than any of the other factors tested, which is consistent with our previous in vivo study that demonstrated the addition of CNTF at the time of MSC injection in a denervated rat hemilarynx (TA) led to greater MSC survival when compared to other trophic factors. 17 No previous studies have investigated therapeutic CNTF delivery for RLN injury, although multiple investigations have studied the effects of other neurotrophic factors such as IGF-1 and neurotrophin-3 on RLN regeneration. [12] [13] [14] 26 Because CNTF had not been previously studied for RLN injury, the motoneuron assays described in the Experiments to Address Specific Aim 1B section were essential to determine if CNTF at physiologic concentrations would have a positive effect on CNX motoneuron outgrowth. In this model, CNTF was shown to promote motoneuron elongation (longest neurite) and branching. Furthermore, additional studies within our laboratory have recently found CNTF to consistently have a greater positive effect on CNX motoneuron outgrowth than IGF-1 or other classic neurotrophins. 20 As is commonly found with neurotrophic factors, the CNTF concentration that promoted motoneuron outgrowth was very specific (50 ng/mL), and positive outgrowth effects were absent at lower and higher concentrations (although the differences between tested concentrations was 10-fold). From a translational standpoint, these findings suggest that in vivo models may face a major challenge to develop a genetic model for introducing CNTF with a resultant CNTF concentration and intramuscular distribution that is optimal for promoting reinnervation throughout a laryngeal muscle. In our animal experiments, we suspect that the high variability in motor endplates with nerve contact within individual TA specimens in the CNTF-treated groups was directly related to variability in CNTF concentrations throughout the TA muscles. Fig. 13 . Endogenous neurotrophic factor (NF) expression from denervated thyroarytenoid (TA) specimens. (A) Because there was a several-fold difference in insulin-like growth factor 1 (IGF-1) expression compared to brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF), IGF-1 is represented with its unique y-axis. At 4 months, reverse transcriptasepolymer chain reaction (RT-PCR) demonstrates increased IGF-1 expression (above) from the denervated TA in the animals who had received ciliary neurotrophic factor (CNTF)-muscle stem cell (MSC) injections (*P < .05). In comparison, the animals treated with MSCs alone (middle) and those animals injected with saline (left) demonstrated similar levels of IGF-1. The arbitrary values of mRNA expression for all NFs were determined based on glyceraldehyde-3-phosphate dehydrogenase as a standard internal control. (B) At 4 months, RT-PCR also demonstrated increased BDNF expression from the denervated TA in the animals who had received CNTF-MSC injections, whereas the GDNF expression showed no difference between groups (*P < .05). For the denervated TA muscles treated with MSCs alone (enhanced green fluorescent protein [EGFP]) and saline, no significant differences were noted between BDNF and GDNF expression levels.
In designing a vector model to engineer the MSCs to secrete CNTF, many options were contemplated and several were tested within the experiments to address specific aim 2. Although plasmid has strong safety features, our experiments demonstrated poor transfection efficiency and unstable gene expression in MSCs in vitro, limiting the utility of plasmid for the in vivo investigations. Regarding viral vectors, a replication-defective adenoviral vector is plagued by safety issues, low transduction rates, and immunogenic reaction. 27, 28 Adenoassociated viral vector has a stronger safety profile, but many humans carry neutralizing antibodies that inactivate the vector. 29, 30 Replication-defective retroviruses were initially attractive tools for gene therapy because of their ability to integrate into genomic DNA, with the risk for insertional mutagenesis thought to be low. Our laboratory previously used a retroviral vector to program MSCs to secrete EGFP for cellular tracking purposes, supporting the feasibility of effectively using this vector with primary MSCs. 17 However, clinical trials involving ex vivo, retrovirally mediated transfer of the interleukin-2 receptor gamma chain gene into CD34þ cells resulted in several patients developing leukemia due to vector insertional activation of the LMO2 proto-oncogene, 31, 32 leading to serious concerns about standard retroviral vector safety. Within the retroviral vector class, the lentiviral vector remains a promising candidate for gene delivery, as certain modifications of the lentiviral vector can result in enhanced safety profiles. For example, deletion of promoter and enhancer elements from the U3 region of the long terminal repeat produces a self-inactivating lentivector that is less likely to result in insertional mutagenesis. Nonintegrating forms of lentiviral vector can also be constructed via selected mutations of the lentiviral integrase protein, thereby preventing integration and risk of insertional mutagenesis, while still permitting effective transgene expression. Lentiviral vectors can also be pseudotyped with envelope proteins or hybrid combinations of envelope proteins from murine and nonmurine viruses, facilitating tissue-specific targeting. 33 Although vesicular stomatitis virus glycoprotein (VSVG) is most widely used, it is not optimal for many applications. For example, in our preliminary investigations with primary MSCs, we found transduction efficiency with VSVG pseudotyped lentivirus to be approximately 50%, whereas transduction efficiency was consistently over 90% with amphotropic (pCAG 4 AMP) pseudotyped lentivirus. This high transduction efficiency with the MSCs was critical, as it allowed for a therapeutic number of NF-secreting MSCs to rapidly be obtained in culture (<3 weeks), which will ultimately be extremely important for clinical translation of such a model.
In reviewing the results of the animal study, the CNTF-MSC treatment appeared to significantly promote reinnervation based on LEMG and immunohistochemistry findings. First, at 2 months, the CNTF group and CNTF-VNC groups both had had greater recruitment in the TA muscle complex than the saline controls (P ¼ .02 and .04, respectively). Second, by 4 months 3/5 animals in the CNTF group and 3/5 animals in the CNTF-VNC groups had TA sections that were classified as strongly reinnervated (>66% of motor endplates with nerve contact), which was significantly greater than that found in the saline and EGFP-MSC control sections. It likely that the CNTF-treated TAs no longer showed appreciable differences on LEMG at 4 months because with all denervated TAs having partial to strong reinnervation, the four-point LEMG rating scale was not sensitive enough to detect subtle differences. 25 Based on our previous experience with LEMG in this animal model, waveform size has often been noted to reflect the timing of reinnervation, with nascent or small motor units detected early in the course of reinnervation, and large (giant) motor units demonstrated as reinnervation matures. In the current study, giant units were more often detected in the denervated TA than the denervated PCA at both time points, potentially suggesting the TA reinnervation preceded that of the PCA. Most notably, the CNTF-MSC group demonstrated more giant units in the TA muscles at both time points when compared to the TA muscles of the other treatment groups (EGFP or saline), suggesting preferential early reinnervation in the CNTF-MSC treated TA muscles. In contrast, the VNC-treated PCA muscles demonstrated much smaller units, with only one animal (11%) with giant units at 2 months and minimal recruitment on LEMG at 2 months ( Fig. 8 ). However, by 4 months 45% of TA muscles demonstrated giant units and differences in recruitment were no longer appreciable with LEMG ( Fig. 12 ). Taken together, these findings suggest that VNC treatment at the administered dose had delayed but not completely inhibited reinnervation of the left PCA.
We initially hypothesized that vocal fold adductor activity may be restored if we were to selectively enhance reinnervation to selected laryngeal muscles with NFsecreting MSCs after RLN injury while simultaneously inhibiting antagonistic reinnervation (synkinesis). Although normal motion was not restored in any of the animals, one unexpected finding on videolaryngoscopy was the presence of a brief adductor twitch in some animals during respiration. We were initially concerned that this could represent Bernoulli's principle; however, the animals with adductor twitches did have LEMGs demonstrating corresponding simultaneous bursts of activity in the adductor complex, thereby supporting active muscular contraction rather than passive motion. In all of the animals, to help delineate the source of EMG activity, we transected the sources of incoming neural supply to the larynx while continuously monitoring the left TA muscles. This approach revealed that many of the animals had reinnervation through the pathway of the ipsilateral RLN. However, nearly half of the animals had at least some persistent continuous LEMG firing of the left TA complex after ipsilateral RLN transection, which did not silence until cutting the pathway of the ipsilateral SLN. Because the LEMG was not quantitative, the methodology did not exclude the possibility of both the RLN and SLN contributing to TA reinnervation in these cases. Just as the investigation of Hydman and colleagues suggested that the SLN contributes to reinnervation of the PCA by intramuscular sprouting after RLN injury, 9 our findings suggest that an analogous phenomenon may occur within the TA complex after RLN injury. Certainly, reinnervation by more than one source is highly feasible based on the multiple communicating branches that exist between the SLN and RLN. 34 In addition, variable ratios of reinnervation from the SLN and RLN could potentially explain the strong reinnervation and inherent variability of firing patterns that characterizes LEMG findings after RLN injury.
Considering this animal model is preliminary in nature and unrefined from a standpoint of optimizing CNTF concentration and distribution, finding significant reinnervation enhancement is promising and warrants further investigations to optimize effectiveness. For example, although CNTF expression from the CNTF-MSC-injected TA muscles at 4 months (over 3 months after the CNTF-MSC injection) was substantially elevated ( Fig. 12) , future studies will be important to determine how this increase in CNTF expression correlates with the CNTF protein concentration throughout the TA muscle complex, as the response to CNTF was highly concentration specific (Fig. 4) . The findings from the RT-PCR studies also revealed that injection of CNTF-MSCs leads to increased expression of other neurotrophic factors, including IGF-1 and BDNF, up to 4 months after treatment. Although the mechanism of this is unclear, the extracellular signal-regulated protein kinase (ERK) pathway (a member of mitogen-activated protein kinase family) may be directly or indirectly activated by the CNTF-expressing MSCs, as ERK activation results in increased expression of factors such as BDNF that are essential to Schwann cell and neuronal regeneration. 35, 36 A future goal will be to identify the optimal concentration of CNTF for enhancement of reinnervation in vivo, which can then be targeted by titrating the number of CNTF-expressing MSCs injected. For example, although we selected 10 6 cells to inject into the TA based on previous studies in our laboratory using nonmodified MSCs, 16, 17 the number of cells could be readily increased or decreased to optimize the CNTF concentration in the tissues, and the cells could be more evenly distributed with multi-injector techniques to improve the effectiveness and consistency of this model.
Although this investigation targeted reinnervation of the adductor muscle group after unilateral RLN injury as proof of concept, the model ultimately may be most clinically useful for enhancing PCA reinnervation in cases of bilateral true vocal fold paralysis. As reinnervation procedures such as phrenic nerve grafting techniques have now evolved to the point of achieving dynamic abduction in many cases, 11 the microenvironmental addition of trophic factors via stem cell vectors may be a means of consistently enhancing and directing neuronal regeneration at the time of reinnervation surgery. An analogous approach could be applicable to directing reinnervation after laryngeal transplantation. 37 Thus, incorporation of stem cell vectors for microenvironmental guidance of reinnervation has a wide range of potential future neurolaryngologic roles.
Stem cell therapies and cellular vectors for gene delivery will inevitably be part of our future therapeutic armamentarium, but we need to translate from bench to bedside, which involves extensive experimental troubleshooting, and ultimately overcoming a tremendous number of regulatory hurdles. Although the current studies involved laryngeal delivery of therapeutic substance(s) via autologous MSCs for the treatment of vocal fold paralysis, the model of delivering therapeutic proteins via cellular vectors may ultimately be applicable to other areas of laryngology, such as controlling respiratory papillomatosis recurrence or providing adjuvant therapy for laryngeal squamous cell carcinoma. The model is readily clinically translatable based on the ease of procurement of large quantities of autologous MSCs, and the technical ease of delivery via laryngeal injection. In fact, if this model is applied to humans, surgeries would be limited to a small skeletal muscle biopsy that can be derived under local anesthetic in the office, and a laryngeal injection. The autologous nature of the MSCs also obviates risk of adverse reaction or rejection, and MSCs are ideal for gene delivery because they rapidly proliferate in culture and have innate features that protect against tumorigenesis when injected in vivo. Thus, this model is highly feasible and holds great therapeutic potential for a wide range of applications.
CONCLUSION
The current investigations demonstrated that CNTF is a strong promoter of MSC survival and CNX outgrowth in vitro, and CNTF-secreting MSCs can be used therapeutically to enhance reinnervation to select muscles after RLN injury in vivo. Although this model focused on enhancing TA reinnervation as proof of concept, it may ultimately lead to a minimally invasive approach for enhancing reinnervation of selected laryngeal muscles, potentially providing an adjuvant therapy for reinnervation procedures. The basic model of safe and effective therapeutic gene delivery via MSCs (cellular vectors) may also be applicable to a wide variety of other otolaryngologic disorders.
